Earnings call transcript: Nano Dimension Q3 2025 revenue surges, stock reacts

Nano Dimension posted Q3 2025 revenue of $26.9 million, up 81% year-over-year driven primarily by the Markforged acquisition (about $17.5M contribution), while standalone revenue fell roughly 37%; the company reported an EPS loss of $0.13 (missing estimates) and an adjusted EBITDA loss of $16.6M. Management highlighted a cash balance of $515.5M, ongoing share repurchases, and cost-reduction plans targeting 10–15% OPEX savings, and provided Q4 guidance of $31.5–33.5M revenue, 47–48.5% gross margin and an improved adjusted EBITDA loss of $12–14M. The print underscores acquisition-fueled top-line growth but persistent core-business weakness and integration/profitability risks—near-term upside depends on realizing synergies from Markforged and outcomes of a strategic-alternatives review led by Guggenheim and Houlihan Lokey.

Analysis

Nano Dimension reported Q3 2025 revenue of $26.9 million, an 81% year-over-year increase driven primarily by the inclusion of Markforged ($17.5 million contribution), while standalone revenue declined roughly 37% to about $9.4 million. The company posted an EPS loss of $0.13, missing analyst expectations, and an adjusted EBITDA loss of $16.6 million; the stock fell 1.3% in after‑hours trading to $1.52 and sits within a 52-week range of $1.31–$2.74.

Management provided Q4 guidance of $31.5–$33.5 million revenue (roughly 21% sequential growth at the midpoint), gross margin of 47%–48.5%, operating expenses of $28–$29 million and an improved adjusted EBITDA loss of $12–$14 million, reflecting targeted OPEX savings of 10%–15%. The balance sheet is a clear strength with $515.5 million in cash, cash equivalents, and investment securities, and management has repurchased shares during and after the quarter, while a strategic‑alternatives review is underway with Guggenheim and Houlihan Lokey.

Primary execution risks are integration of Markforged and realization of projected synergies, the continuing decline in standalone revenue (tariffs and softer European demand), and ongoing profitability pressure despite cost actions. Near‑term upside is conditional on management hitting Q4 guidance and translating OPEX reductions into sustained margin improvement; absent clear delivery, investor confidence may remain muted until the strategic review yields a definitive outcome.

Key Decisions for Investors

• Monitor Q4 results closely and only increase exposure if revenue prints near the midpoint and adjusted EBITDA moves materially toward the guided $12–$14 million loss range
• Recognize the $515.5 million cash buffer and active buybacks as supportive but prefer a size‑limited or hedged position given the EPS miss and 37% standalone revenue decline
• Treat developments from the strategic‑alternatives review as potential catalysts; reassess position promptly on any announced M&A, divestiture, or sale outcomes
• If maintaining exposure, set explicit risk controls (stop‑loss or options hedge) and track standalone revenue, gross margin trajectory, and realized OPEX savings each quarter